Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany

被引:57
作者
Aziz, N. Ahmad [1 ,2 ]
Corman, Victor M. [3 ,4 ,5 ]
Echterhoff, Antje K. C. [1 ]
Mueller, Marcel A. [3 ,4 ,5 ]
Richter, Anja [3 ,4 ]
Schmandke, Antonio [1 ]
Schmidt, Marie Luisa [3 ,4 ,5 ]
Schmidt, Thomas H. [1 ]
de Vries, Folgerdiena M. [1 ]
Drosten, Christian [3 ,4 ,5 ]
Breteler, Monique M. B. [1 ,6 ]
机构
[1] German Ctr Neurodegenerat Dis DZNE, Populat Hlth Sci, Bonn, Germany
[2] Univ Bonn, Dept Neurol, Fac Med, Bonn, Germany
[3] Charite Univ Med Berlin, Inst Virol, Berlin, Germany
[4] Humboldt Univ, Freie Univ Berlin, Berlin Inst Hlth, Berlin, Germany
[5] German Ctr Infect Res DZIF, Berlin, Germany
[6] Univ Bonn, Fac Med, Inst Med Biometry Informat & Epidemiol IMBIE, Bonn, Germany
关键词
D O I
10.1038/s41467-021-22351-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
To estimate the seroprevalence and temporal course of SARS-CoV-2 neutralizing antibodies, we embedded a multi-tiered seroprevalence survey within an ongoing community-based cohort study in Bonn, Germany. We first assessed anti-SARS-CoV-2 immunoglobulin G levels with an immunoassay, followed by confirmatory testing of borderline and positive test results with a recombinant spike-based immunofluorescence assay and a plaque reduction neutralization test (PRNT). Those with a borderline or positive immunoassay result were retested after 4 to 5 months. At baseline, 4771 persons participated (88% response rate). Between April 24(th) and June 30(th), 2020, seroprevalence was 0.97% (95% CI: 0.72-1.30) by immunoassay and 0.36% (95% CI: 0.21-0.61) when considering only those with two additional positive confirmatory tests. Importantly, about 20% of PRNT+ individuals lost their neutralizing antibodies within five months. Here, we show that neutralizing antibodies are detectable in only one third of those with a positive immunoassay result, and wane relatively quickly. Population-based studies of SARS-CoV-2 seroprevalence are needed to understand levels of immunity and antibody dynamics. Here, the authors show that the seroprevalence in Bonn, Germany was low (<1%) following the first epidemic wave, and that neutralising antibodies waned within a few months.
引用
收藏
页数:10
相关论文
共 47 条
[1]   Realising the potential of SARS-CoV-2 vaccines-a long shot? [J].
不详 .
LANCET RESPIRATORY MEDICINE, 2021, 9 (02) :117-117
[2]  
[Anonymous], 2020, TEMPORAL OVERVIEW SA
[3]   SeroTracker: a global SARS-CoV-2 seroprevalence dashboard [J].
Arora, Rahul K. ;
Joseph, Abel ;
Van Wyk, Jordan ;
Rocco, Simona ;
Atmaja, Austin ;
May, Ewan ;
Yan, Tingting ;
Bobrovitz, Niklas ;
Chevrier, Jonathan ;
Cheng, Matthew P. ;
Williamson, Tyler ;
Buckeridge, David L. .
LANCET INFECTIOUS DISEASES, 2020, 21 (04) :E75-E76
[4]   Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].
Baden, Lindsey R. ;
El Sahly, Hana M. ;
Essink, Brandon ;
Kotloff, Karen ;
Frey, Sharon ;
Novak, Rick ;
Diemert, David ;
Spector, Stephen A. ;
Rouphael, Nadine ;
Creech, C. Buddy ;
McGettigan, John ;
Khetan, Shishir ;
Segall, Nathan ;
Solis, Joel ;
Brosz, Adam ;
Fierro, Carlos ;
Schwartz, Howard ;
Neuzil, Kathleen ;
Corey, Larry ;
Gilbert, Peter ;
Janes, Holly ;
Follmann, Dean ;
Marovich, Mary ;
Mascola, John ;
Polakowski, Laura ;
Ledgerwood, Julie ;
Graham, Barney S. ;
Bennett, Hamilton ;
Pajon, Rolando ;
Knightly, Conor ;
Leav, Brett ;
Deng, Weiping ;
Zhou, Honghong ;
Han, Shu ;
Ivarsson, Melanie ;
Miller, Jacqueline ;
Zaks, Tal .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416
[5]  
Bobrovitz N, LESSONS RAPID SYSTEM, DOI [10.1101/2020.05.10.20097451(2020, DOI 10.1101/2020.05.10.20097451(2020]
[6]   A Tale of 2 Studies: Study Design and Our Understanding of Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence COMMENT [J].
Boyce, Ross M. ;
Shook-Sa, Bonnie E. ;
Aiello, Allison E. .
CLINICAL INFECTIOUS DISEASES, 2021, 73 (09) :E3124-E3126
[7]   SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 [J].
Braun, Julian ;
Loyal, Lucie ;
Frentsch, Marco ;
Wendisch, Daniel ;
Georg, Philipp ;
Kurth, Florian ;
Hippenstiel, Stefan ;
Dingeldey, Manuela ;
Kruse, Beate ;
Fauchere, Florent ;
Baysal, Emre ;
Mangold, Maike ;
Henze, Larissa ;
Lauster, Roland ;
Mall, Marcus A. ;
Beyer, Kirsten ;
Roehmel, Jobst ;
Voigt, Sebastian ;
Schmitz, Juergen ;
Miltenyi, Stefan ;
Demuth, Ilja ;
Mueller, Marcel A. ;
Hocke, Andreas ;
Witzenrath, Martin ;
Suttorp, Norbert ;
Kern, Florian ;
Reimer, Ulf ;
Wenschuh, Holger ;
Drosten, Christian ;
Corman, Victor M. ;
Giesecke-Thiel, Claudia ;
Sander, Leif Erik ;
Thiel, Andreas .
NATURE, 2020, 587 (7833) :270-+
[8]   The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic [J].
The COVID-19 Host Genetics Initiative .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (06) :715-718
[9]   Not just antibodies: B cells and T cells mediate immunity to COVID-19 [J].
Cox, Rebecca J. ;
Brokstad, Karl A. .
NATURE REVIEWS IMMUNOLOGY, 2020, 20 (10) :581-582
[10]   An interactive web-based dashboard to track COVID-19 in real time [J].
Dong, Ensheng ;
Du, Hongru ;
Gardner, Lauren .
LANCET INFECTIOUS DISEASES, 2020, 20 (05) :533-534